This review highlights the expanding armamentarium of medical and device-based therapies for stroke prevention in atrial fibrillation, particularly relevant for patients with contraindications to traditional anticoagulation.
Cardiac embolism, primarily from atrial fibrillation (AF), is implicated in a quarter of all ischemic strokes. In the setting of AF, contraindications to traditional therapies can create a clinical dilemma when choosing an agent for secondary stroke prophylaxis. Newer horizons in the medical and surgical management of AF have helped us choose from a wide variety of available therapies, the best possible management. In this article, we review the current trends in AF management including newer oral anticoagulants as well as surgical devices from a neurologist's view.
No takes yet. Share an insight, caveat, or question.
Hedna et al. (2012) conducted a review in Atrial fibrillation. Newer oral anticoagulants and surgical devices was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: